She-Juan An
Overview
Explore the profile of She-Juan An including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Chen Z, Zhong W, Zhang X, Su J, Yang X, Chen Z, et al.
Oncologist
. 2012 Jun;
17(7):978-85.
PMID: 22673630
Background: Non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor heterogeneity in EGFR mutations is one potential explanation...
22.
Zhou Q, Zhang X, Chen Z, Yin X, Yang J, Xu C, et al.
J Clin Oncol
. 2011 Jul;
29(24):3316-21.
PMID: 21788562
Purpose: Our aim was to determine whether abundance of epidermal growth factor receptor (EGFR) mutations in tumors predicts benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs) for advanced non-small-cell lung...
23.
Nie Q, Yang X, An S, Zhang X, Yang J, Zhong W, et al.
Eur J Cancer
. 2011 May;
47(13):1962-70.
PMID: 21616658
Background: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of efficacy for EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR and cytochrome...
24.
An S, Huang Y, Chen Z, Su J, Yang Y, Chen J, et al.
Med Oncol
. 2011 Apr;
29(2):627-32.
PMID: 21461966
We sought to find blood-based biomarkers that can be used to predict efficacy in advanced non-small cell lung cancer patients treated with bevacizumab plus chemotherapy. Blood was collected before treatment...
25.
Cheng H, An S, Dong S, Zhang Y, Zhang X, Chen Z, et al.
J Hematol Oncol
. 2011 Jan;
4:5.
PMID: 21255411
Background: Chemotherapy combined concurrently with TKIs produced a negative interaction and failed to improve survival when compared with chemotherapy or TKIs alone in the treatment of non-small cell lung cancer...
26.
Cheng H, An S, Zhang X, Dong S, Zhang Y, Chen Z, et al.
Cancer Chemother Pharmacol
. 2010 May;
67(3):637-46.
PMID: 20495920
Purpose: In clinical trials, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) administered concomitantly with first-line cytotoxicity chemotherapy failed to confer a survival benefit to patients with non-small-cell lung...
27.
Wang K, Zhou Q, Guo A, Xu C, An S, Wu Y
Immunol Invest
. 2009 Oct;
38(7):665-80.
PMID: 19811429
Objective: The development of immunotherapy for malignancy is greatly limited by the characteristic weak antigenicity of tumors. The primary goal of this study was to circumvent the isolation and purification...
28.
Huang Y, An S, Chen Z, Wu Y
Br J Clin Pharmacol
. 2009 Sep;
68(3):464-7.
PMID: 19740406
No abstract available.
29.
An S, Chen Z, Lin Q, Su J, Chen H, Lin J, et al.
BMC Cancer
. 2009 May;
9:144.
PMID: 19435508
Background: Kinase insert domain-containing receptor (KDR) plays a critical role in the metastasis of cancer and is used as a molecular target in cancer therapy. We investigated the characteristics of...
30.
Li R, An S, Chen Z, Zhang G, Zhu J, Nie Q, et al.
Hum Pathol
. 2008 Aug;
39(12):1792-801.
PMID: 18715616
Real-time reverse transcription polymerase chain reaction and immunohistochemistry were used to evaluate the messenger RNA (mRNA) and protein expression levels of total cyclin D1 and its splice variants (cyclin D1a...